A Double Blind, Randomized, Active-controlled, Phase 3 Study to Confirm the Safety and Efficacy of CJ-12420 in Patients With Erosive Esophagitis

Trial Profile

A Double Blind, Randomized, Active-controlled, Phase 3 Study to Confirm the Safety and Efficacy of CJ-12420 in Patients With Erosive Esophagitis

Recruiting
Phase of Trial: Phase III

Latest Information Update: 02 Jan 2017

At a glance

  • Drugs Tegoprazan (Primary) ; Esomeprazole
  • Indications Erosive oesophagitis
  • Focus Therapeutic Use
  • Sponsors CJ HealthCare
  • Most Recent Events

    • 02 Jan 2017 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top